Preliminary Program
Friday, May 09, 2025
| 09.45-10.00h | Welcome and Introduction | |
|---|---|---|
| Nuclear Medicine meets Neuro-Oncology. | Nathalie L. Albert (Munich), Matthias Preusser (Vienna) |
| 10.00-12.00h | Radioligand therapy – the future of precision oncology | |
|---|---|---|
| Chairs: Eng-Siew Koh (Sydney), Marcus Hacker (Vienna) | ||
| RLT works – current evidence. | Michael Hofman (Melbourne) | |
| Next generation RLT – trends in nuclear medicine. | Ken Herrmann (Essen) | |
| Bringing RLT into the CNS – a promising concept in neuro-oncology? | Nathalie Albert (Munich) | |
| Panel discussion | all session speakers |
| 12.00-13.00h | NMN Lunch |
|---|
| 13.00-14.00h | Understanding theranostics | |
|---|---|---|
| Chairs: Wim Oyen (Arnhem/Milan), Jörg Tonn (Munich) | ||
| Radiopharmaceuticals explained | Karolien Goffin (Leuven) | |
| From reactor to patient – how do we get radionuclides into clinical routine? | Andrew Scott (Melbourne) | |
| Panel discussion: All you need to know about RLT – frequently asked questions in clinical routine. | All session speakers + Kathy Oliver (IBTA), Francesco Cicone (Catanzaro), Roberta Rudà (Turin) |
| 14.00-15.00h | Proffered papers I: Hot data and burning questions | |
|---|---|---|
| Chairs: Jolanta Kunikowska (Warsaw), Giuseppe Minniti (Rome) | ||
| Oral presentations from selected abstracts | (length and format TBD depending on number of submissions) |
| 15.00-15.45h | NMN Coffee |
|---|
| 15.45-17.00h | Proffered papers II: Hot data and burning questions | |
|---|---|---|
| Chairs: Susan Chang (San Francisco), Martin van den Bent (Rotterdam) | ||
| Oral presentations from selected abstracts | (length and format TBD depending on number of submissions) |
| 17.00-18.30h | Posters viewing: Drinks and Science |
|---|
| From 19.00h | Networking Event “Heurigen” |
|---|
Saturday, May 10, 2025
| 09.00-10.00 | Coffee with the Editors | |
|---|---|---|
| Ulrike Harjes (Nature Medicine), Susan Chang (Neuro-Oncology), Cheryl Lai (Lancet Oncology) |
| 10.00-12.00h | Enhancing treatment efficacy | |
|---|---|---|
| Chairs: Patrick Wen (Boston), Emilie Le Rhun (Zurich) | ||
| Intraarterial injections of therapeutic radioligands – challenges and opportunities. | Arthur Braat (Utrecht) | |
| Overcoming the blood-brain-barrier – what´s the fuss about FUS? | Graeme Woodworth (Baltimore) | |
| Local applications of RLT – is this the way to go? | Bogdana Suchorska (Heidelberg) | |
| Enhancing radiosensitivity and overcoming treatment resistance | Erik Sulman (New York) |
| 12.00-13.30h | NMN Lunch |
|---|
| 13.30-15.00h | Lessons learned from other disciplines | |
|---|---|---|
| Chairs: Nelleke Tolboom (Utrecht), Anna Berghoff (Vienna) | ||
| The trialist’s perspective: how to generate evidence. | Michael Weller (Zurich) | |
| The oncologist’s perspective: adapting the success of antibody drug conjugates. | Matthias Preusser (Vienna) | |
| The neuropathologist’s perspective: targets and biomarkers | Felix Sahm (Heidelberg) | |
| The non-oncological perspective: lessons learned from neurodegenerative disorders. | Matthias Brendel (Munich) |
| 15.00-15.45h | NMN Coffee |
|---|
| 15.45-17.00h | PET imaging of CNS tumors: must have or nice to have? | |
|---|---|---|
| Chairs: Michael Weller (Zurich), Johnny Duerinck (Brussels) | ||
| Overview RANO PET working group activities | Norbert Galldiks (Cologne) | |
| Point-counterpoint debates | ||
| Point: the case for amino acid PET imaging of glioblastoma | Nathalie Albert (Munich) | |
| Counterpoint: the case against amino acid PET imaging of glioblastoma | Marjolein Geurts (Rotterdam) | |
| Call to action: how to proceed | Panel discussion |
| 17.00-17.30h | Conclusions and Farewell Drinks | |
|---|---|---|
| Nathalie L. Albert (Munich), Matthias Preusser (Vienna) |